Erasca, Inc. (ERAS)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 07, 2025

$1.59

P/E Ratio

N/A

Market Cap

$449.54M

Description
Add to research

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerERAS
  • Price$1.59-4.79%

Trading Information

  • Market cap$449.54M
  • Float57.80%
  • Average Daily Volume (1m)1,442,287
  • Average Daily Volume (3m)1,365,089
  • EPS-$0.83

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$31.20M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$36.40M
  • EV$504.94M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.00
  • Debt/Equity11.76
Documents
Add to research